Telix Pharmaceuticals Ltd ADR (TLX): Next-Year EPS Estimate 154.21%
As of 2026-07-31, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 154.21%. Featured in our EPS revision report on 2026-04-13.
On 2026-07-28, analyst consensus for TLX's next-year EPS growth shifted from 119.25% to 154.21% — a positive change of 34.96 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at 274.06%.
What's Driving This
The primary driver is the 34.96-percentage-point upgrade to next-year EPS growth, now at 154.21%. The revision follows Telix's strategic radiopharma collaboration with Regeneron and FDA acceptance of the NDA for TLX101-Px, both supporting higher growth expectations. The elevated estimate has persisted, indicating continued momentum beyond the initial upgrade.
Generated 2026-07-31 from news as of 2026-07-31
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 154.21%
- EPS growth this year
- 274.06%
- EPS next quarter (est)
- N/A
- Last price
- $9.89
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-31 | 154.21% | 274.06% | N/A | $9.89 |
| 2026-07-30 | 154.21% | 274.06% | N/A | $10.06 |
| 2026-07-29 | 154.21% | 274.06% | N/A | $10.10 |
| 2026-07-28 | 154.21% | 274.06% | N/A | $10.19 |
| 2026-07-27 | 119.25% | 301.82% | N/A | $9.98 |
| 2026-07-26 | 119.25% | 301.82% | N/A | $10.22 |
| 2026-07-24 | 119.25% | 301.82% | N/A | $10.22 |
| 2026-07-23 | 117.86% | 304.18% | N/A | $10.51 |
| 2026-07-22 | 117.86% | 304.18% | N/A | $10.32 |
| 2026-07-21 | 121.88% | 312.31% | N/A | $10.92 |
| 2026-07-20 | 136.73% | 313.86% | N/A | $10.51 |
| 2026-07-19 | 173.98% | 268.67% | N/A | $10.46 |
| 2026-07-17 | 173.98% | 268.67% | N/A | $10.46 |
| 2026-07-16 | 204.98% | 257.92% | N/A | $10.83 |
| 2026-07-15 | 204.98% | 257.92% | N/A | $11.29 |
| 2026-07-14 | 204.98% | 257.92% | N/A | $11.02 |
| 2026-07-13 | 204.98% | 257.92% | N/A | $10.97 |
| 2026-07-12 | 225.86% | 249.55% | N/A | $11.14 |
| 2026-07-09 | 225.86% | 249.55% | N/A | $11.78 |
| 2026-07-08 | 225.86% | 249.55% | N/A | $11.55 |
| 2026-07-07 | 225.86% | 249.55% | N/A | $11.74 |
| 2026-07-06 | 225.86% | 249.55% | N/A | $12.15 |
| 2026-07-05 | 225.86% | 249.55% | N/A | $11.87 |
| 2026-07-02 | 225.86% | 249.55% | N/A | $11.87 |
| 2026-07-01 | 223.59% | 250.87% | N/A | $11.84 |
| 2026-06-30 | 223.59% | 250.87% | N/A | $11.53 |
| 2026-06-29 | 223.59% | 250.87% | N/A | $11.30 |
| 2026-06-28 | 223.59% | 250.87% | N/A | $10.66 |
| 2026-06-25 | 227.44% | 250.37% | N/A | $10.86 |
| 2026-06-24 | 227.44% | 250.37% | N/A | $10.90 |
Reports Featuring TLX
Recent News
- Telix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswire
- FDA Accepts NDA for TLX101-Px (Pixclara)GlobeNewswire
Screen Performance
Aggregate stats across all 1903 tickers our top-EPS-revision screen has flagged over the past 121 days.
- Median return since detection
- +1.2%
- % of tickers in the green
- 52%
- Median return on winners
- +18.8%
- Large revisions captured
- 1198
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-07-31, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 154.21%, based on analyst consensus.
When was the latest EPS estimate revision for TLX?▾
The most recent revision occurred on 2026-07-28, when analysts adjusted the next-year EPS growth estimate from 119.25% to 154.21%.
What sector and industry does Telix Pharmaceuticals Ltd ADR belong to?▾
Telix Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TLX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.